The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

Streetwise Reports (11/16/2022)

4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

Streetwise Reports (11/14/2022)

This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

UK Co. Buys NARCAN® Nasal Spray Maker

Streetwise Reports (11/14/2022)

Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.

Tags: Biotechnology / Pharmaceuticals

Biologics Co. Doubles Revenue in Q3/22

Streetwise Reports (11/11/2022)

ADMA Biologics Inc. shares traded 27.5% higher after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.

Tags: Biotechnology / Pharmaceuticals

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Streetwise Reports (11/11/2022)

With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Trades 200% Higher

Streetwise Reports (11/10/2022)

Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.

Tags: Biotechnology / Pharmaceuticals

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion

Clive Maund (11/09/2022)

Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Tags: GoldBiotechnology / PharmaceuticalsCritical MetalsTechnologyBase MetalsSilver

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion

Penny Queen (11/09/2022)

With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Offers US$295M for Ophthalmology Co.

Streetwise Reports (11/08/2022)

Shares of Oyster Point Pharma Inc. traded 38.5% higher after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Signs Global License Deal for Eye Drops

Streetwise Reports (11/08/2022)

Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances.

Tags: Biotechnology / Pharmaceuticals

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines

Streetwise Reports (11/03/2022)

Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Earns Big Rewards from Global License Deal

Streetwise Reports (11/02/2022)

Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Trades 39% Higher

Streetwise Reports (11/01/2022)

Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant.

Tags: Biotechnology / Pharmaceuticals

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

Research Report

(10/31/2022)

This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial

Streetwise Reports (10/28/2022)

Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer.

Tags: Biotechnology / Pharmaceuticals

Potential ROI With German Biopharma Co. Notable

Research Report

Dr. Elemer Piros (10/27/2022)

This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results

Streetwise Reports (10/25/2022)

Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age.

Tags: Biotechnology / Pharmaceuticals

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'

Contributed Opinion

Clive Maund (10/25/2022)

Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Shows Large Potential Return

Research Report

Dr. Joseph Pantginis (10/21/2022)

Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Target Price Over Three Times Current

Research Report

Dr. Joseph Pantginis (10/13/2022)

Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s Shares Roll to New 52-Week High Price

Streetwise Reports (10/12/2022)

Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Partners With Merck for Combo Drug Trial

Research Report

Dr. Joseph Pantginis (10/12/2022)

With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Chen Reveals His Picks for Last Quarter

Streetwise Reports (10/11/2022)

Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies.

Tags: SilverBiotechnology / Pharmaceuticals

US Firm Teams up With Leading Pharma Co. To Delay T1D Onset

Streetwise Reports (10/07/2022)

Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Drug Showing 'Early Signs of Benefit'

Research Report

Dr. Elemer Piros (10/06/2022)

With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 26 to 50 of 115 Prev Next